Molecular epidemiology and mechanisms of antimicrobial resistance in Pseudomonas aeruginosa isolates causing burn wound infection in Iran

Journal of Chemotherapy

Volumn 26, Issue 4, 2014, Pages 222-228

  Fazeli, Hossein ^a   Sadighian, Hooman ^a,b   Esfahani, Bahram Nasr ^a   Pourmand, Mohammad Reza ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

MexXY; MLST; PER; Pseudomonas aeruginosa; ST235

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; PIPERACILLIN;

AMPC GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BETA LACTAMASE GENE; BURN INFECTION; CHEMICAL ANALYSIS; CLINICAL ARTICLE; GENE; GENE EXPRESSION; HUMAN; MEXY GENE; MULTILOCUS SEQUENCE TYPING; NONHUMAN; OPRD GENE; PREVALENCE; PSEUDOMONAS AERUGINOSA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; EPIDEMIOLOGY; GENETICS; IRAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; REAL TIME POLYMERASE CHAIN REACTION; WOUND INFECTION;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IRAN; PSEUDOMONAS AERUGINOSA; REAL-TIME POLYMERASE CHAIN REACTION; WOUND INFECTION;

EID: 84903385078     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000132     Document Type: Article

References (36)

1. Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagace-Wiens P, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother. 2010;54(11):4684-93.
2. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care associated infections caused by antibiotic-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2010;54:109-15.
3. Livermore DM. Of Pseudomonas, porins, pumps, and carbapenems. J Antimicrob Chemother. 2001;47(3):247-50.
4. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to2001. Antimicrob Agents Chemother. 2003;47:1681-8.
5. Vahdani M, Azimi L, Asghari B, Bazmi F, Rastegar Lari A. Phenotypic screening of extended-spectrum b-lactamase and metallo-b-lactamase in multidrug-resistant Pseudomonas aeruginosa from infected burns. Ann Burns Fire Disasters. 2012;25(2):78-81.
6. Bush K, Jacoby GA. Updated functional classification of blactamases. Antimicrob Agents Chemother. 2010;54(3):969-76.
7. Poole K, Frank D, Tolmasky M. Pseudomonas aeruginosa: resistance to the max. Front Microbio. 2011;2(65):1-13.
8. Strateva T, Yordanov D. Pseudomonas aeruginosa-a phenomenon of bacterial resistance. J Med Microbiol. 2009;58(9):1133-48.
9. Endimiani A, Luzzaro F, Pini B, Amicosante G, Rossolini GM, Toniolo AQ. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum b-lactamase. BMC Infect Dis. 2006;6:52.
10. Mirsalehian A, Feizabadi M, Nakhjavani FA, Jabalameli F, Goli H, Kalantari N. Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum b-lactamase-producing Pseudomonas aeruginosa strains isolated from burn patients. Burns. 2010;36(1):70-4.
11. Kalantar E, Taherzadeh S, Ghadimi T, Soheili F, Salimizand H, Hedayatnejad A. Pseudomonas aeruginosa, an emerging pathogen among burn patients in Kurdistan Province, Iran. Southeast Asian J Trop Med Public Health. 2012;43(3):712-7.
12. Morita Y, Tomida J, Kawamura K. MexXY multidrug efflux system of Pseudomonas aeruginosa. Front Microbio. 2012;3(408):1-13.
13. Llanes C, Hocquet D, Vogne C, Benali-Baitich D, Neuwirth C, Plésiat P. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother. 2004;48(5):1797-802.
14. Poole K, Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Top Med Chem. 2001;1:59-71.
15. Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM. Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Inter J Med Microbiol. 2012;302:63-8.
16. Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J Clin Microbiol. 2004;42(12):5644-9.
17. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 23rd Informational Supplement M100-S23. Wayne, PA: CLSI; 2013.
18. Lang BJ, Aaron SD, Ferris W, Hebert PC, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2000;162:2241-5.
19. Aktaş Z, Poirel L, Salcioǧlu M, Ozcan PE, Midilli K, Bal C, et al. PER-1-and OXA-10-like b-lactamases in ceftazidimeresistant Pseudomonas aeruginosa isolates from intensive care unit patients in Istanbul, Turkey. Clin Microbiol Infect. 2005;11(3):193-8.
20. Bert F, Branger C, Lambert-Zechovsky N. Identification of PSE and OXA b-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism. J Antimicrob Chemother. 2002;50(1):11-8.
21. Bogaerts P, Huang T, Rodriguez-Villalobos H, Bauraing C, Deplano A, Struelens MJ, et al. Nosocomial infections caused by multidrug-resistant Pseudomonas putida isolates producing VIM-2 and VIM-4 metallo-b-lactamases. J Antimicrob Chemother. 2008;61(3):749-51.
22. Jeong SH, Lee K, Chong Y, Yum JH, Lee SH, Choi HJ, et al. Characterization of a new integron containing VIM-2, a metallo-b-lactamase gene cassette, in a clinical isolate of Enterobacter cloacae. J Antimicrob Chemother. 2003;51(2):397-400.
23. Deschaght P, Baere TD, Simaey LV, Daele SV, Baets FD, Vos DD, et al. Comparison of the sensitivity of culture, PCR and quantitative real-time PCR for the detection of Pseudomonas aeruginosa in sputum of cystic fibrosis patients. BMC Microbiol. 2009;29(9):244-53.
24. Oh H, Stenhoff J, Jalal S, Wretlind B. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb Drug Resist. 2003;9(4):323-8.
25. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother. 2011;55(5):1906-11.
26. Pfaffi MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):2003-7.
27. Feil EJ, Enright MC. Analyses of clonality and the evolution of bacterial pathogens. Curr Opin Microbiol. 2004;7:308-13.
28. Samuelsen O, Toleman MA, Sundsfjord A, Rydberg J, Leegaard TM, Walder M, et al. Molecular epidemiology of metallo-b-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob Agents Chemother. 2010;54(1):346-52.
29. Empel J, Filczak K, Mrowka A, Hryniewicz W, Livermore DM, Gniadkowski M. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum b-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J Clin Microbiol. 2007;45(9):2829-34.
30. Yousefi S, Nahaei MR, Farajnia S, Aghazadeh M, Iversen A, Edquist M, et al. A multiresistant clone of Pseudomonas aeruginosa sequence type 773 spreading in a burn unit in Orumieh, Iran. APMIS. 2013;121(2):146-52.
31. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2006;50:1633-41.
32. Bradford PA. Extended-spectrum b-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933-51.
33. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-86.
34. Bouthors AT, Dagoneau N, Blanchard S, Naas T, Nordmann P, Jarlier V, et al. Role of residues 104, 164, 166, 238, 240 in the substrate profile of PER-1 b-lactamase hydrolysing thirdgeneration cephalosporins. Biochem J. 1998;330:1443-9.
35. Poirel L, Naas T, Guibert M, Chaibi EB, Labia R, Nordmann P. Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum b-lactamase encoded by an Escherichia coli integron gene. Antimicrob Agents Chemother. 1999;43:573-81.
36. Hocquet D, Roussel-Delvallez M, Cavallo JD, Plesiat P. MexAB-OprM-and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin. Antimicrob Agents Chemother. 2007;51:1582-3.